



Indraprastha Medical Corporation Limited

(Indraprastha Apollo Hospitals)

Regd. Office: Sarita Vihar, Delhi-Mathura Road, New Delhi – 110 076 (India) Corporate Identity Number: L24232DL1988PLC030958 Phone:91-11-26925858,26925801,Fax: 91-11-26823629

E-mail: imcl@apollohospitals.com, Website: https://www.apollohospitals.com/delhi/

Ref: IMCL/CS/BM/2024

30th October, 2024

The Manager Listing Department BSE Limited Phiroze Jeejeebhoy Towers Dalal Street, Mumbai, Maharashtra -400001

Scrip Code: 532150

The Manager
Listing Department
National Stock Exchange of India Limite
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra East,
Mumbai, Maharashtra – 400051
Symbol: INDRAMEDCO

Re: Outcome of the Board Meeting held on 30th October, 2024

Dear Sir,

This is to inform that the Board of Directors of the Company has, at its meeting held on Wednesday, 30th October, 2024 (i.e. today), inter-alia, considered and approved the Unaudited Financial Results for the quarter & half year ended 30th September, 2024, along with the Limited Review Report of the statutory auditor.

We are enclosing herewith the Un-audited Financial Results for the quarter & half year ended 30th September, 2024, along with a copy of the Limited Review Report by the Statutory Auditors of the Company.

The Board meeting commenced at 3.00 p.m. and ended at 4.45 p.m.

This is for your information and record.

Thanking You,

Yours sincerely,

For Indraprastha Medical Corporation Limited

Priya Ranjan AVP - Corporate Affairs & Legal (Company Secretary & Compliance Officer)

Encl. as above

S.N. Dhawan & CO LLP

Chartered Accountants

2[™] Floor, 51-52, Sector-18, Phase IV, Udyog Vihar, Gurugram, Haryana 122016, India

Tel: +91 124 481 4444

Limited Review Report on Unaudited Quarterly and Year to Date Results

To the Board of Directors of Indraprastha Medical Corporation Limited

- 1. We have reviewed the accompanying statement of unaudited financial results of Indraprastha Medical Corporation Limited ("the Company") for the quarter ended September 30, 2024 and year to date results for the period April 01, 2024 to September 30, 2024 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India ("the SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. This Statement which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant Rules issued thereunder; and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
- 3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S.N. Dhawan & CO LLP

Chartered Accountants

Firm Registration No.: 000050N/N500045

OHAWAN & CO

Bhaskar Sen

Partner

Membership No.: 096985 UDIN 24096985BKBWIY6118

Place: New Delhi

Date: October 30, 2024

INDRAPRASTHA MEDICAL CORPORATION LIMITED

Registered office: Sarita Vihar, Delhi Mathura Road, New Delhi - 110076 Corporate Identity Number: L24232DL1988PLC030958 Phone: 91-11-26925858, 26925801, Fax: 91-11-26823629




E-mail: imclshares@apollohospitals.com, Website: delhi.apollohospitals.com

Statement of Unaudited Financial Results for the Quarter and Half-year ended 30th September, 2024

Amount (Rs. in crore)

							(Rs. in crore)
S.	Particulars		Quarter ended			· · · · · · · · · · · · · · · · · · ·	Year ended
No.		30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024 (Audited)
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	
1	Revenue from operations	349.82	347.86	317.00	697.68	623.51	1244.70
2	Other income	6.05	5.12	4.17	11.17	7.73	16.89
3	Total income	355.87	352.98	321.17	708.85	631.24	1261.59
4	Expenses						
	a) Cost of materials consumed	56.23	58.93	56.99	115.16	111.17	217.19
	b) Employee benefits expense	71.61	66.59	67.07	138.20	130.34	261.61
	c) Professional charges to doctors	91.16	90.67	77.59	181.83	154.62	311. 7 9
	d) Finance costs	1.59	1.61	0.85	3.20	1.63	4.06
	e) Depreciation and amortisation expense	11.17	11.04	10.03	22.21	19.84	40.08
	f) Other expenses	67.18	64.55	64.99	131.73	129.76	260.75
	Total expenses	298.94	293.39	277.52	592.33	547.36	1095.48
5	Profit before exceptional items and tax	56.93	59.59	43.65	116.52	83.88	166.11
6	Exceptional items	-	-	-	-	-	_
7	Profit before tax (PBT)	56.93	59.59	43.65	116.52	83.88	166.11
8	Tax expense						
	Current tax	15.20	15.21	11.27	30.41	22.18	43.03
	Deferred tax	(0.67)	(0.39)	(0.47)	(1.06)	(1.65)	(0.88)
9	Profit for the period after tax (PAT)	42.40	44.77	32.85	87.17	63.35	123.96
10	Other comprehensive income						
	(i) Items that will not be reclassified to profit or loss	(1.60)	2.64	(0.29)	1.04	(0.75)	2.47
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.40	(0.66)	0.07	(0.26)	0.19	(0.62)
	Total other comprehensive income (Net of tax expenses)	(1.20)	1.98	(0.22)	0.78	(0.56)	1.85
11	Total comprehensive income for the period	41.20	46.75	32.63	87.95	62.79	125.81
12	Paid-up equity share capital (Face value Rs. 10/- each)	91.67	91.67	91.67	91.67	91.67	91.67
13	Reserves (excluding Revaluation Reserves) as shown in the audited balance sheet of previous year						386.09
14	Earnings per share Basic and Diluted (Rs.) - Not Annualised	4.63	4.88	3.58	9.51	6.91	13.52





	Statement of Assets and Liabilities:	Amoun	t (Rs. in crore
	Particulars	Unaudited	Audited
		30.09.2024	31.03.2024
	ASSETS		
1	Non-current assets		
	(a) Property, plant and equipment	308.52	311.9
	(b) Right-of-use asset	32.02	33.9
	(c) Capital work-in-progress	0.25	0.4
	(d) Intangible assets	0.83	1.0
	(e) Financial assets	41.05	62.6
	(f) Other non-current assets	3.99	5.1
		386.66	415.2
	Comment		
2	Current assets (a) Inventories	7.00	7.5
	(b) Financial assets	7.86	7.5
	(i) Trade receivables	75 14	50.4
	(ii) Cash and cash equivalents	75.14 66.77	58.4 61.6
	(iii) Bank balances other than (ii) above	242.58	162.8
	(iv) Other financial assets	8.06	6.4
	(c) Current tax assets (Net)	5.16	0.4
- 1	(d) Other current assets	14.09	11.1
	(a) Onler current nocco	419.66	307.9
			
\exists	TOTAL OF ASSETS	806.32	723.2
		1	
1.	EQUITY AND LIABILITIES		
_	Equity		
	(a) Equity share capital	91.67	91.6
ŀ	(b) Other equity	432.76	386.0
		524.43	477.70
	Liabilities		
2	Non-current liabilities		
	(a) Financial liabilities		
	(i) Security deposits	0.89	0.88
	(ii) Lease liabilities	30.99	32.27
	(b) Provisions	27.91	27.19
	(c) Deferred tax liabilities (Net)	18.92	19.72
		78.71	80.06
	Current liabilities		
	(a) Financial liabilities	i	
i	(i) Trade payables		
	- Total outstanding dues of micro and small enterprises	2.20	0.99
	- Total outstanding dues of creditors other than micro and small enterprises	130.31	132.20
	(ii) Lease liabilities	1.75	1.68
	(iii) Other financial liabilities	0.33	5.03
- 1	(b) Other current liabilities	64.64	22.75
- 1	(c) Provisions	3.95	2.16
ľ	(d) Current tax liabilities (Net)	-	0.58
		203.18	165.42
4	TOTAL OF EQUITY AND LIABILITIES	22.25	200
	TOTAL OF EQUITY AND LIABILITIES	806.32	723.24
	TOTAL OF EQUITY AND LIABILITIES OF A COLOR OF THE PROPERTY OF	ln	-

	Statement of Cash Flows	Amount (Rs. in crore)		
	Particulars	Half-Year ended		Year ended
		30.09.2024	30.09.2023	31.03.2024
<u> </u>		(Unaudited)	(Unaudited)	(Audited)
١.	CARVATA ON THE CARVATA ON THE ATTENDED A CONTRACTOR			
A .	CASH FLOW FROM OPERATING ACTIVITIES			
Ì	Profit before tax	116.52	83.88	166.11
	Add:			
	Depreciation and amortization expense	22.21	19.84	40.08
	Interest expense	1.50	0.20	1.06
	Loss on disposal of assets	0.24	0.51	1.17
	•			
	Deduct:			
	Interest income	11.17	7.73	16.89
	Operating profit before working capital changes	129.30	96.70	191.53
	Adjustments for: Trade and other receivables	(17.70)	2.50	13.87
	Trade and other receivables Trade payables	(17.76) 3.45	37.26	40.67
	Inventories	(0.33)	0.48	0.92
1	Cash generated from operations	114.66	136.94	246.99
	Cush generated from operations	114.00	150.71	210.55
٠	Deduct:			
	Interest paid	-	-	0.01
	Income tax paid	36.16	20.27	46.83
	Net cash generated from operating activities	78.50	116.67	200.15
	CACH ELOM EDOM INVESTING A CTIVITYE			
В.	CASH FLOW FROM INVESTING ACTIVITIES	(20.26)	(25.60)	((0.20)
	Purchase of Property, plant & equipment and intangible assets (Net of sale)	(20.26)	(35.60)	(69.39)
	Movement in other bank balances Interest received	(58.13) 7.76	(96.36) 4.15	(101.35) 12.31
	Net cash used in investing activities	(70.63)	(127.81)	(158.43)
	The cash asea in investing activities	(70.03)	(127.01)	(100.10)
C.	CASH FLOW FROM FINANCING ACTIVITIES			
	Lease payments	(1.21)	(2.82)	(3.79)
	Interest paid	(1.49)	(0.19)	(1.05)
	Dividend paid	-	(0.03)	(27.54)
	Net cash used in financing activities	(2.70)	(3.04)	(32.38)
	Net increase / (decrease) in cash and cash equivalents	5.17	(14.18)	9.34
	Opening cash and cash equivalents	61.60	52.26	52.26
	Closing cash and cash equivalents	66.77	38.08	61.60
	Components cash and cash equivalents	_		
	Cash balance on hand	0.44	0.18	0.39
	Balance with banks	66.33	37.90	61.21

Notes:

- 1. The above financial results were reviewed by the Audit Committee and have been approved by the Board of Directors at their meeting held on 30th October, 2024.
- 2. The Company operates in a single segment i.e. Healthcare and hence, does not have any additional disclosures to be made under Ind AS 108 on Operating Segments.
- $3. \quad \text{The Company does not have any subsidiary/associate/joint venture company (ies), as on 30^{th} September, 2024.}$
- ${\bf 4.} \quad \hbox{Previous year/period figures have been regrouped / rearranged wherever necessary}.$


Place: New Delhi Date: 30th October, 2024 Shivakumar Pattabhiraman (Managing Director) DIN: 08570283



INDRAPRASTHA MEDICAL CORPORATION LIMITED

Registered office : Sarita Vihar, Delhi Mathura Road, New Delhi - 110076

 $Corporate\ Identity\ Number: L24232DL1988PLC030958$





Extract of Statement of unaudited Financial Results for the Quarter and Half-year ended 30th September, 2024

Amount (Rs. in crore)

S.	Particulars	Quarter ended			Half-Year ended		Year ended
No.		30.09.2024 (Unaudited)	30.06.2024 (Unaudited)	30.09.2023 (Unaudited)	30.09.2024 (Unaudited)	30.09.2023 (Unaudited)	31.03.2024 (Audited)
1	Total income from operations (Net)	355.87	352.98	321.17	708.85	631.24	1261.59
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	56.93	59.59	43.65	116.52	83.88	166.11
	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	56.93	59.59	43.65	116.52	83.88	166.11
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	42.40	44.77	32.85	87.17	63.35	123.96
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after Tax)]	41.20	46.75	32.63	87.95	62.79	125.81
6	Paid-up Equity share capital (Face value Rs. 10/- each)	91.67	91.67	91.67	91.67	91.67	91.67
7	Reserves (excluding Revaluation Reserves) as shown in the audited balance sheet of previous year						386.09
	Earnings per share (of Rs. 10/- each) (for continuing and discontinued operations) - Basic & Diluted	4.63	4.88	3.58	9.51	6.91	13.52

The above is an extract of the detailed format of unaudited financial results for the quarter and half-year ended 30th September, 2024, filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the unaudited financial results for the quarter and half-year ended 30th September, 2024, are available on the Stock Exchange websites (www.bseindia.com and www.nseindia.com) and on the company's website.

Place: New Delhi

Date: 30th October, 2024

Shivakumar Pattabhiraman

(Managing Director)

DIN: 08570283